肝细胞癌转化治疗序贯手术的围手术期安全性单中心回顾性分析
该单中心回顾性病例系列纳入45例初始不可切除肝细胞癌患者,接受转化治疗后序贯手术。转化治疗客观缓解率48.9%,疾病控制率100%,术后病理学完全缓解率20.0%。治疗相关不良反应和围手术期并发症风险可控,为患者提供手术机会和长期生存可能。
要点
- 转化治疗后客观缓解率48.9%,疾病控制率100%,术后pCR率20.0%。
- 转化治疗期间84.4%出现治疗相关不良反应,围手术期55.6%出现手术并发症。
- pCR组无病生存优于MPR及非MPR组,但三组总体生存无显著差异。
核心结论
- 肝细胞癌转化治疗的治疗相关不良反应及围手术期并发症风险可控,为初始不可切除患者提供手术机会和长期生存可能。
研究设计与样本
- 回顾性病例系列研究,纳入2021年1月至2023年4月中国医学科学院肿瘤医院肝胆外科45例初始不可切除肝细胞癌患者,男41例、女4例,年龄54.5(12.5)岁。
主要发现
- 转化治疗后客观缓解率48.9%(22/45),疾病控制率100%(45/45)。
- 术后病理学完全缓解率20.0%(9/45),主要病理学缓解率26.7%(12/45)。
- 转化治疗阶段84.4%(38/45)出现治疗相关不良反应,以肝功能损伤、高血压病、低蛋白血症为主。
- 围手术期55.6%(25/45)出现手术相关并发症,常见为低蛋白血症、腹水、感染。
- 1年和3年总体生存率分别为93.33%和80.42%,无病生存率分别为87.69%和70.54%。
关键数值与推荐
- pCR组无病生存时间长于MPR组及未达到MPR组(P值均<0.05)。
- 三组患者总体生存时间差异无统计学意义(P>0.05)。
临床怎么用
- 对初始不可切除肝细胞癌可考虑转化治疗序贯手术,需监测肝功能损伤、高血压、低蛋白血症等不良反应及围手术期低蛋白血症、腹水、感染等并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the perioperative safety of patients with hepatocellular carcinoma (HCC) undergoing conversion therapy followed by sequential surgical resection. Methods: This study was designed as a retrospective case series. Clinical and pathological data were retrospectively collected from 45 patients with initially unresectable HCC who received conversion therapy followed by surgical treatment at the Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, between January 2021 and April 2023. The cohort comprised 41 males and 4 females, with an age(M(IQR)) of 54.5(12.5)years (range: 31 to 74 years). According to the Child-Pugh classification, 44 patients were classified as grade A and one as grade B. The median maximum tumor diameter was 8.05(5.82)cm (range: 4.2 to 19.2 cm). Regarding the China Liver Cancer staging system: 24 cases (53.3%) were at stage Ⅰb, 5 cases (11.1%) at stage Ⅱa, 10 cases (22.2%) at stage Ⅱb, and 6 cases (13.4%) at stage Ⅲa. The clinical characteristics, efficacy and adverse reactions of conversion therapy, as well as perioperative and postoperative follow-up outcomes were analyzed. Overall survival (OS) and disease-free survival (DFS) curves were plotted using the Kaplan-Meier method. For comparion of survival rates among the three groups, if the initial P value was <0.05, multiple comparison correction was performed, followed by pairwise comparisons using the Log-rank test. Results: After conversion therapy, the objective response rate was 48.9% (22/45), and the disease control rate reached 100% (45/45). The postoperative pathological complete response (pCR) rate was 20.0% (9/45), and major pathological response (MPR) rate was 26.7% (12/45). During conversion therapy, 84.4% (38/45) patients developed treatment-related adverse reactions, mainly including liver dysfunction, hypertension, and hypoalbuminemia. In perioperative period, 55.6% (25/45) patients experienced surgery-related complications, with the most common being hypoalbuminemia, ascites, and infection. The 1-year and 3-year OS rates for the 45 patients were 93.33% and 80.42%, respectively, while the 1-year and 3-year DFS rates were 87.69% and 70.54%, respectively. The DFS in pCR group was significantly longer than that in MPR and non-MPR group (all P<0.05). However, there was no statistically significant difference in OS among the three groups (P>0.05). Conclusions: The risks of treatment-related adverse reactions and perioperative complications in conversion therapy for HCC are manageable. This therapeutic approach provides surgical opportunities and the potential for long-term survival for patients with initially unresectable HCC. 目的: 探讨转化治疗序贯手术治疗的肝细胞癌患者的围手术期安全性。 方法: 本研究为回顾性病例系列研究。回顾性收集2021年1月至2023年4月中国医学科学院肿瘤医院肝胆外科收治的行转化治疗序贯手术治疗的45例初始不可切除肝细胞癌患者的临床和病理学资料。男性41例,女性4例,年龄[M(IQR)]54.5(12.5)岁(范围:31~74岁)。肝功能Child-Pugh分级A级44例,B级1例;肿瘤最大径为8.05(5.82)cm(范围:4.2~19.2 cm)。中国肝癌分期Ⅰb期24例(53.3%),Ⅱa期5例(11.1%),Ⅱb期10例(22.2%),Ⅲa期6例(13.4%)。分析患者的临床特点、转化治疗效果及不良反应、围手术期和术后随访情况。采用Kaplan-Meier法绘制总体生存曲线和无病生存曲线。当进行三组患者生存率比较时,若P<0.05,则进行多重比较校正,再采用Log-rank检验进行两两比较。 结果: 转化治疗后客观缓解率为48.9%(22/45),疾病控制率达100%(45/45);术后病理学完全缓解(pCR)率为20.0%(9/45),主要病理学缓解(MPR)率为26.7%(12/45)。转化治疗阶段84.4%(38/45)的患者出现治疗相关不良反应,以肝功能损伤、高血压病、低蛋白血症为主。围手术期55.6%(25/45)的患者出现手术相关并发症,发生率较高的并发症为低蛋白血症、腹水、感染。45例患者1年和3年的总体生存率分别为93.33%和80.42%,无病生存率分别为87.69%和70.54%。术后pCR组的无病生存时间长于MPR组及未达到MPR组(P值均<0.05),三组患者总体生存时间的差异无统计学意义(P>0.05)。 结论: 肝细胞癌转化治疗的治疗相关不良反应及围手术期并发症风险可控,为初始不可切除肝细胞癌患者提供了手术机会和长期生存可能。.
引用
- Wei ZW, Cai JQ. [The perioperative safety analysis of conversion therapy for liver cancer: a single-center retrospective study]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 41771522. doi:10.3760/cma.j.cn112139-20250815-00404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。